Donepezil therapy in patients with vascular and post-traumatic cognitive impairment: Some clinical observations;Tratamiento con donepecilo en pacientes con deterioro cognitivo vascular y postraumático: Observaciones clínicas

Revista de Neurologia

Volumn 38, Issue 10, 2004, Pages 938-943

  Olazarán Rodríguez, Javier ^a,c   Cruz Orduna I ^b   Jimenez Martin I ^b  

^a IMSALUD   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CEP Moratalaz   (Spain)

Author keywords

Donepezil; Post traumatic dementia; Treatment; Vascular dementia

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL;

ADULT; AGED; AGGRESSIVENESS; ALZHEIMER DISEASE; APATHY; ARTICLE; ATTENTION; BEHAVIOR; CASE REPORT; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE EXACERBATION; DRUG TOLERABILITY; FEMALE; FUNCTIONAL DISEASE; HUMAN; IRRITABILITY; MALE; MEMORY; MULTIINFARCT DEMENTIA; TREATMENT OUTCOME;

EID: 3142696431     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3810.2003573     Document Type: Article

References (23)

1. Bryson HM, Benfield P. Donepezile. Drugs Aging 1997; 10: 234-9.
2. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In The Cochrane Library. Oxford: Update Software; 2002.
3. Schneider LS. Donepezil in the treatment of Alzheimer's disease. In Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al, eds. Evidence-based dementia practice. Oxford: Blackwell; 2002. p. 473-83.
4. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61: 479-86.
5. Arciniegas DB, Topkoff JL, Anderson CA, Filley CM, Adler LE. Normalization of P50 physiology by donepezil hydrochloride in traumatic brain injury patients [abstract]. J Neuropsychiatry Clin Neurosci 2001; 13: 140.
6. Sachdev P, Trollor J, Looi JCL. Treatment of reversible or arrestable dementias. In Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al, eds. Evidence-based dementia practice. Oxford: Blackwell; 2002. p. 615-38.
7. Leys D, Englund E, Erkinjuntii T. Vascular dementia. In Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al, eds. Evidence-based dementia practice. Oxford: Blackwell; 2002. p. 260-87.
8. Mendez MF. Miscellaneous causes of dementia. In Whitehouse PJ, ed. Dementia. Philadelphia: FA Davis; 1993. p. 337-58.
9. Olazarán J, Muñiz R. El papel de los centros de día en el tratamiento de los trastornos neuroconductuales crónicos. Actualizaciones en Neurología, Neurociencias y Envejecimiento 2003; 1: 277-81.
10. Kaye J. Summary, practical recommendations and conclusions. In Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al, eds. Evidence-based dementia practice. Oxford: Blackwell; 2002. p. 603-7.
11. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
13. Benedet MJ, Alejandre MA. TAVEC, test de aprendizaje verbal España-Complutense. Madrid: TEA; 1997.
14. Golden CJ. Stroop. Test de colores y palabras. Manual. Madrid: TEA; 1994.
15. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease. The disability assessment for dementia. Am J Occup Ther 1999; 53: 471-81.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory. Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
17. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003; 60: 1183-5.
18. López OL. La base neurobiológica de las alteraciones conductuales de la enfermedad de Alzheimer y en otras demencias. In Alberca R, ed. Tratamiento de las alteraciones conductuales en la enfermedad de Alzheimer y en otros procesos neurológicos. Madrid: Panamericana; 2002. p. 47-63.
19. Berthier ML, Hinojosa J, Martín MC, Fernández I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003; 60: 1218-9.
20. Mimura M, Albert ML, McNamara P. Toward a pharmacotherapy for aphasia. In Kirshner J, ed. Handbook of neurological speech and language disorders. New York: Marcel Dekker; 1995. p. 465-82.
21. Hutchinson CW, Nathan PJ, Mrazek L, Stough C. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology 2001; 155: 440-2.
22. Nathan PJ, Baker A, Carr E, Earle J, Jones M, Nieciecki M, et al. Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor. Hum Psychopharmacol Clin Exp 2001; 16: 481-3.
23. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinical significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17: 947-65.